Vivani Medical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VANI research report →
Range $4 – $4
Price Chart
About the company
Vivani Medical, Inc. , a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases.
- CEO
- Adam Mendelsohn
- IPO
- 2014
- Employees
- 42
- HQ
- Alameda, CA, US
Get TickerSpark's AI analysis on VANI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $102.83M
- P/E
- -3.56
- PEG
- -0.10
- P/S
- 0.00
- P/B
- 7.77
- EV/EBITDA
- -3.84
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -161.39%
- ROIC
- -91.52%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-424,000+0.0%
- Op Income
- $-27,556,000
- Net Income
- $-26,609,000-13.3%
- EPS
- $-0.43+0.0%
- OCF Growth
- -17.0%
- FCF Growth
- -19.4%
- 52W High
- $1.66
- 52W Low
- $0.80
- 50D MA
- $1.16
- 200D MA
- $1.23
- Beta
- 3.32
- RSI (14)
- 54
- Avg Volume
- 228.83K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Second Sight reported a weak Q4 revenue quarter, but highlighted encouraging Orion study results, progress toward FDA alignment, and first approvals for next-generation wearables.· March 19, 2020
- Q4 net sales were $0.5 million versus $1.8 million a year ago, with three implants recognized on a GAAP basis.
- Orion’s sixth EFS subject completed 12-month testing, and management said the overall data were positive enough to support moving toward a U.S. pivotal study.
- The company received conditional FDA approval and CE Mark certification for next-generation Argus 2s wearables, with a limited launch planned later this year.
- FDA discussions on the pivotal trial’s safety endpoint are still open; management now expects alignment by the end of Q3.
- Cash was $11.3 million at December 31, 2019, and management said the fourth-quarter cash burn was $7.1 million with runway into Q2 2020.
Net sales were $0.5 million in Q4 2019 versus $1.8 million in Q4 2018. Revenue was recognized for three implants on a GAAP basis, with an average selling price of $166,000, compared with 16 devices at an ASP of $110,000 in the prior-year quarter. R&D expense, net of grants, was $4.1 million versus $2.4 million a year ago; clinical and regulatory expense was $1.0 million versus $1.2 million; selling and marketing expense was $1.0 million versus $2.4 million; and G&A was $2.3 million versus $2.5 million. As of December 31, 2019, cash and cash equivalents were $11.3 million, fourth-quarter cash burn was $7.1 million, and the company said it had runway into Q2 2020. For 2020, management said operating cash burn would be a little higher than the $27.6 million in 2019 due to heavier R&D and clinical work, but it did not provide revenue or EPS guidance.
Will McGuire framed the quarter around continued execution on Orion and a leadership transition. He said the company has made significant progress with R&D and FDA discussions, and emphasized that Orion’s clinical results and the new wearables approvals strengthen the path forward. His tone was upbeat but measured, stressing confidence in the team and saying he did not expect the organization to miss a beat under interim leadership.
John Blake focused on reimbursement, liquidity, and expense trends. He said the company had productive meetings with CMS, including discussion of national coverage for Orion, and noted outreach to private payers and lawmakers around breakthrough-device reimbursement. Financially, he highlighted the $11.3 million cash balance, $7.1 million fourth-quarter cash burn, and the expectation that 2020 operating cash burn will be slightly higher than 2019’s $27.6 million because of R&D and clinical spending; he also said G&A should remain flat going forward.
Analysts pressed on CEO succession, and management said the board is only in the early stages of the search, with Greg Williams serving as interim CEO. They also asked about FDA safety endpoints; management said the key unresolved issue is the acceptable serious adverse event rate for a first-in-class technology, plus related trial-size and post-market requirements, and expects alignment by the end of Q3. On timing, management said the IDE filing has shifted to the first half of 2021, not because of technical problems, but because of ongoing discussions with FDA; they also said COVID-19 has begun to complicate validation work and will delay some activities.
The positive case is that Orion’s six-subject EFS produced encouraging 12-month data, including improvements on all three visual function measures in the last subject and generally positive FLORA outcomes across the group. Management also said the FDA and CE Mark wins on the next-generation wearables remove an important hurdle and provide a base technology for the pivotal trial.
The main risks are regulatory timing and liquidity. FDA agreement on the safety endpoint is still unresolved, the IDE timeline has slipped to the first half of 2021, and COVID-19 has paused FLORA 20 validation efforts. Financially, sales remain very small, burn is high relative to cash, and the company said it only had runway into Q2 2020 while it worked on financing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 42.0%
- Shares Outstanding
- 90.20M
- Float Shares
- 37.84M
of shares held by institutions
38 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.55M | ▲ 210.79K |
| Vanguard Capital Management LLC | 1.44M | ▼ 330.70K |
| Geode Capital Management, LLC | 518.62K | ▼ 69.12K |
| Commonwealth Equity Services, LLC | 320.56K | ▼ 10.00K |
| Blackrock, Inc. | 293.19K | ▼ 8.64K |
| Vanguard Fiduciary Trust Co | 232.32K | ▼ 93.14K |
| Monetary Management Group Inc | 193.98K | 0 |
| Susquehanna International Group, Llp | 155.78K | ▲ 127.43K |
| State Street Corp | 154.97K | 0 |
| Jane Street Group, LLC | 122.34K | ▲ 122.34K |
| Northern Trust Corp | 116.91K | 0 |
| Arax Advisory Partners | 100.00K | ▲ 100.00K |
Held by 23 ETFs
Biggest fund positions in VANI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Mendelsohn Aaron | other | 99,010 |
| Nov 19, 26 | Williams Gregg | buy | 85,265 |
| Nov 18, 26 | Williams Gregg | buy | 33,169 |
| Nov 18, 26 | Mendelsohn Aaron | other | 99,010 |
| Nov 17, 26 | Williams Gregg | buy | 29,929 |
| Nov 16, 26 | Williams Gregg | buy | 2,100 |
| Nov 13, 26 | Williams Gregg | buy | 48,100 |
| Nov 12, 26 | Dwyer Donald | buy | 15,000 |
| Nov 12, 26 | Dwyer Donald | buy | 5,000 |
| Oct 15, 26 | Mendelsohn Aaron | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VANI coverage
Recent articles, reports, and earnings notes.
No research on VANI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VANI report →Vivani Medical Announces Private Placement Equity Financing
globenewswire.com · Nov 16
Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027
benzinga.com · Nov 12
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects
globenewswire.com · Nov 12
Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 11
Vivani Medical Announces Participation in Upcoming Investor Conferences
globenewswire.com · Sep 3
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 13
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
globenewswire.com · Aug 6
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
marketbeat.com · Jul 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.